Noteworthy Thursday Option Activity: UUUU, MRNA, PFE

Moderna (MRNA) and Pfizer (PFE) are experiencing significantly elevated options trading activity, with MRNA's options volume representing 53.3% of its average daily stock volume and PFE's at 50.6%. This heightened interest is particularly concentrated in long-dated call options, notably the MRNA $37 strike expiring July 2025 and the PFE $22 strike expiring August 2025, suggesting increased speculative or directional positioning in these pharmaceutical companies.

Analysis

Moderna (MRNA) and Pfizer (PFE) are exhibiting significant and concentrated derivatives market activity. Options volume in MRNA has reached 53.3% of its average daily share volume, while PFE's has hit 50.6%, indicating a substantial shift in trading interest towards options over direct equity. This activity is not diffuse; it is notably focused on long-dated call options. For MRNA, a significant portion of the volume is in the $37 strike calls expiring July 2025, while for PFE, the $22 strike calls expiring August 2025 are attracting heavy trading. The choice of these distant expiration dates, over a year away, suggests that market participants are positioning for potential upside in the underlying stocks over an extended horizon, rather than engaging in short-term tactical trades. This flow of over 1.5 million underlying shares for each of the highlighted contracts could represent speculative bullish bets or institutional positioning ahead of anticipated long-term catalysts.

Key Decisions for Investors

• Investors should monitor these specific long-dated call options as a potential leading indicator of institutional sentiment and watch for corresponding follow-through in the underlying stock price and volume.
• Given the distant expiration dates, it is prudent to investigate the long-term strategic and clinical pipelines for both MRNA and PFE to identify potential catalysts that could be driving this speculative interest.